KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Long-Term Debt Repayments (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of Long-Term Debt Repayments data on record, last reported at $207.8 million in Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments rose 17.56% year-over-year to $207.8 million; the TTM value through Dec 2025 reached $1.3 billion, down 9.67%, while the annual FY2025 figure was $1.3 billion, 9.67% down from the prior year.
  • Long-Term Debt Repayments reached $207.8 million in Q4 2025 per CRL's latest filing, down from $253.8 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $2.5 billion in Q2 2021 and bottomed at $149.4 million in Q1 2025.
  • Average Long-Term Debt Repayments over 5 years is $643.5 million, with a median of $368.9 million recorded in 2022.
  • Peak YoY movement for Long-Term Debt Repayments: skyrocketed 2004.1% in 2021, then plummeted 83.41% in 2023.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $1.1 billion in 2021, then crashed by 61.21% to $408.2 million in 2022, then dropped by 21.43% to $320.8 million in 2023, then plummeted by 44.89% to $176.8 million in 2024, then rose by 17.56% to $207.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were $207.8 million in Q4 2025, $253.8 million in Q3 2025, and $738.3 million in Q2 2025.